GENFIT: Annual Shareholders Meeting of June 11, 2020 – Availability of Preparatory Documents
07 Mai 2020 - 10:15PM
GENFIT: Annual Shareholders Meeting of June 11, 2020 – Availability
of Preparatory Documents
Lille (France); Cambridge
(Massachusetts, United States) — May 7, 2020 —
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases, today announced that it
published in the May 6, 2020’s French legal announcements bulletin
(Bulletin des Annonces Légales Obligatoires) its convening notice
that the Annual Shareholders Meeting will be held on Thursday, June
11, 2020, at 10:00 am, at the Company’s headquarters, located at
Parc Eurasanté, 885 avenue Eugène Avinée in Loos (59120),
France.
Due to the ongoing lockdown and prohibition on
public gatherings currently imposed by the French government to
prevent the spread of Coronavirus (COVID-19), the Board of
Directors of the Company decided the Shareholders Meeting will be
held behind closed doors, meaning without the physical
presence of shareholders and others who are usually entitled to
attend, in accordance with the provisions of Article 4 of Ordinance
No. 2020-321 of March 25, 2020.
The convening notice published in the May 6,
2020 French legal announcements bulletin (Bulletin des Annonces
Légales Obligatoires) and available in the Investors & Media
section of the Company’s website
(https://ir.genfit.com/financial-information/shareholders-meeting)
outlines the procedures by which shareholders may participate in
the Meeting notwithstanding the exceptional measures required in
order to comply with regulatory constraints and ensure the health
and safety of our shareholders.
Shareholders may provide their voting
instructions via the Internet through the VOTACCESS platform. A
tutorial to familiarize shareholders with this online voting
platform will be available in the same section of the website, as
well as a toll-free (France only) number to call with any questions
regarding how to participate in the Meeting.
Documentation regarding the Meeting will be
available to shareholders in accordance with existing regulations,
and available on the Company’s website, in the Investors &
Media section
(https://ir.genfit.com/financial-information/shareholders-meeting).
As announced previously, the 2019 Universal Registration Document
and the Annual Report on Form 20-F will be available at the end of
May.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial of elafibranor in PBC. As part of GENFIT’s
comprehensive approach to clinical management of patients with
NASH, GENFIT is also developing a new, non-invasive blood-based
diagnostic test, NIS4, which, if approved, could enable easier
identification of patients with NASH. With facilities in Lille and
Paris, France, and Cambridge, MA, USA, the Company has
approximately 200 employees. GENFIT is a publicly traded company
listed on the Nasdaq Global Select Market and in compartment B of
Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT).
www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995, with respect
to GENFIT, including forward-looking statements regarding its
financial calendar for 2020. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking
statements. Although GENFIT believes its expectations are
based on the current expectations and reasonable assumptions of the
Company’s management, these forward-looking statements are subject
to numerous known and unknown risks and uncertainties, which could
cause actual results to differ materially from those expressed in,
or implied or projected by, the forward-looking statements. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, biomarkers, progression of, and results from,
its ongoing and planned clinical trials, review and approvals by
regulatory authorities of its drug and diagnostic candidates and
the Company’s continued ability to raise capital to fund its
development, as well as those risks and uncertainties discussed or
identified in the Company’s public filings with the French Autorité
des marchés financiers (“AMF”), including those
listed in Section 4 “Main Risks and Uncertainties” of the Company’s
2018 Registration Document filed with the AMF on February 27, 2019
under n° D.19-0078, which is available on GENFIT’s website
(www.genfit.com) and on the website of the AMF (www.amf-france.org)
and public filings and reports filed with the U.S. Securities and
Exchange Commission (“SEC”), including GENFIT’s
final prospectus dated March 26, 2019, and subsequent filings and
reports filed with the AMF or SEC, or otherwise made public, by
GENFIT. In addition, even if GENFIT’s results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. These forward-looking
statements speak only as of the date of publication of this
document. Other than as required by applicable law, the GENFIT does
not undertake any obligation to update or revise any
forward-looking information or statements, whether as a result of
new information, future events or otherwise.
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Annual Shareholders Meeting on June 11, 2020 –
Availability of Preparatory Documents